BioSpace News Archive

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced that George Dyer, MD was elected to the Company’s Board of Directors at its Annual Meeting of Stockholders held on June 14, 2023.

Taysha Gene Therapies, Inc. announced it will host a virtual R&D Day on Wednesday, June 28, 2023 at 10:00 AM ET to discuss updates on TSHA-120, a self-complimentary intrathecally delivered investigational AAV9 gene therapy in clinical evaluation for GAN, and TSHA-102, a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy in clinical evaluation for Rett syndrome.

Bionomics Limited, a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system disorders with high unmet medical need, announced that it will present at the following upcoming investor conferences in June.

AltruBio Inc. announced that the company will be giving an oral presentation on its immune checkpoint enhancer, ALTB-268, as well as feature a poster on ICE ALTB-168 at the 2023 Federation of Clinical Immunology Societies Annual Meeting, which is being held June 20-23, 2023 in Boston, Massachusetts.

Avenge Bio, Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to AVB-001 for the treatment of patients with mesothelioma.

Addentax Group Corp. announced that it is in advanced discussion with its Company’s Chairman and Chief Executive Officer, Mr. Hong Zhida, to acquire Mr Hong’s partial stake in Shanghai Bao Pharmaceutical Company Limited, via Shenzhen Grandway Capital Management Co., Ltd. Grandway Capital will act as a fund manager..

Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, announced the appointment of Germo Gericke, MD, to its Scientific Advisory Board.

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced that six abstracts revealing benefits of AJOVY injection in patients with migraine will be presented at the 2023 American Headache Society Annual Scientific Meeting, held June 15-18 in Austin, Texas.

Osivax announced that the first participant has been vaccinated in its new Phase 2a clinical trial evaluating broad-spectrum influenza vaccine candidate, OVX836 in combination with Quadrivalent Influenza Vaccines.

Scholar Rock announced that the company granted inducement equity awards covering an aggregate of 216,563 shares of its common stock to 8 newly hired employees, consisting of inducement stock options to purchase an aggregate of 123,750 shares of common stock and inducement restricted stock units, covering an aggregate of 92,813 shares of its common stock.